Source:http://linkedlifedata.com/resource/pubmed/id/18772609
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-9-5
|
| pubmed:abstractText |
Assessment of platelet function is a critical component of the treatment and secondary prevention of cerebral infarction, and measurement of platelet-derived microparticle (PDMP) levels using flow cytometry may be a good indicator of platelet function. However, the flow cytometric analysis is not feasible in a variety of clinical situations. The goal of the present study was to measure PDMP levels using an enzyme-linked immunosorbent assay (ELISA) in chronic cerebral infarction patients and to determine the utility of PDMP level measurement for the monitoring of the effect of cilostazol and aspirin. A crossover study was performed using 4-weeks of aspirin (100 mg/day) and 4-weeks of cilostazol (200 mg/day) in 18 patients. PDMP levels were also measured in 20 volunteers as controls. Experiments demonstrated that PDMP levels were significantly higher in chronic cerebral infarction patients (median 8.8 U/ml, interquartile range 5.1-14.9 U/ml, n=18) than in controls (median 5.5 U/ml, interquartile range 5.0-8.2 U/ml, n=20) (P=0.047). PDMP levels did not decrease after therapy with either aspirin (median 10.9 U/ml, interquartile range 6.2-17.9 U/ml, n=12) or cilostazol (median 9.2 U/ml, interquartile range 6.1-14.3 U/ml, n=12) compared with baseline PDMP levels in the 12 patients who completed this trial (median 11.4 U/ml, interquartile range 5.2-23.7 U/ml, n=12). There were no significant differences in PDMP levels between aspirin and cilostazol (P=0.61). In conclusion, PDMP levels as measured by ELISA were increased in patients with chronic cerebral infarction regardless of the anti-platelet therapy. This methodology may be a useful strategy of assessing platelet function in chronic cerebral infarction patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1883-0498
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
54
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
E55-61
|
| pubmed:meshHeading |
pubmed-meshheading:18772609-Aged,
pubmed-meshheading:18772609-Blood Platelets,
pubmed-meshheading:18772609-Cell-Derived Microparticles,
pubmed-meshheading:18772609-Cerebral Infarction,
pubmed-meshheading:18772609-Chronic Disease,
pubmed-meshheading:18772609-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18772609-Female,
pubmed-meshheading:18772609-Health,
pubmed-meshheading:18772609-Humans,
pubmed-meshheading:18772609-Male,
pubmed-meshheading:18772609-Middle Aged
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Measurement of platelet-derived microparticle levels in the chronic phase of cerebral infarction using an enzyme-linked immunosorbent assay.
|
| pubmed:affiliation |
Division of Neurology, Department of Internal Medicine Kobe University Graduate School of Medicine.
|
| pubmed:publicationType |
Journal Article
|